/
/
First Trispecific Antibody in Multiple Myeloma Enters Development Track
First Trispecific Antibody in Multiple Myeloma Enters Development Track image
First Trispecific Antibody in Multiple Myeloma Enters Development Track
Posted May 16, 2022

 

A new class of drug called trispecific antibodies is opening up in myeloma care with a new announcement by Ichnos Sciences. 

The trispecific antibody targets two areas found on multiple myeloma cells (BCMA and CD38) and joins that with the CD3 T cells. The company's proprietary platform is called BEAT® 2.0 technology. 

Studies in the lab showed that it increased the killing potential of myeloma cells compared to currently approved antibodies used in myeloma, or those currently in myeloma clinical trials. Studies in mouse models also showed superior outcomes. By targeting two antigents found on myeloma cells (BCMA and CD38), it increases the binding the cells and also reduces the opportunity for "off target" side effects. 

The company has not yet submitted its Investigational New Drug (IND) Application to the FDA but has started IND-enabling studies to advance to first-in-human studies next year.

 Monoclonal Antibodies

In myeloma we are familiar with moclonal antibodies (daratumumab and isatuximab) which are now mainstays in myeloma care. In this video, Alex Lesokhin, MD of Memorial Sloan Kettering Cancer Center, Suzanne Lentzsch, MD of Columbia University and Hareth Nahi, MD of the Karolinska Institute share how monocloncal antibodies work. 

Bispecific Antibodies

Bispecific antibodies are moving along in myeloma clinical trials and there are over 9 potential bispecific antibodies being developed for multiple myeloma for a variety of targets (BCMA, GPR5CD and others). The first to become approved later this year may be teclistamab. In this video, Ravi Vij, MD, MBA of Washington University, David Vesole. MD, PhD of MedStar Health, Luciano Costa, MD, PhD of the University of Alabama and Peter Voorhees, MD of Levine help us understand how bispecific antibodies are being used in multiple myeloima.

We look forward to this new class of trispecific antibody drugs progressing in myeloma clinical trials. 

The author Jennifer Ahlstrom

about the author
Jennifer Ahlstrom

Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical research. Founder of Myeloma Crowd by HealthTree and the HealthTree Foundation.

More Myeloma News Articles

Get the latest thought leadership on Myeloma delivered straight to your inbox.

Subscribe to the weekly "HealthTree Community for Myeloma Newsletter" for Myeloma news, life with Myeloma stories, Myeloma clinical trials, Myeloma 101 articles and events with Myeloma experts.

Thanks to our HealthTree Community for Myeloma Sponsors:

Genentech
Abbvie
Bristol Myers Squibb
Janssen Oncology
GSK

Follow Us

facebook instagram twitter youtube

Copyright © 2022 HealthTree Foundation. All Rights Reserved.

The HealthTree Foundation / Myeloma Crowd is a qualified 501(c)(3) tax-exempt organization. Tax ID 45-5354811

 https://www.guidestar.org/profile/45-5354811